 |
17 Diseases |  |
1 Trial |
|
1 Trial |  |
553 News |  |
| «1234567» |
- | Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial completion date, Trial primary completion date: Study to Treat Major Depressive Disorder With a New Medication (clinicaltrials.gov) - Apr 18, 2019
P2, N=48, Recruiting, Sponsor: James Murrough
Trial completion date: May 2019 --> Aug 2019 | Trial primary completion date: Apr 2019 --> Aug 2019
- | Trileptal (oxcarbazepine) / Novartis
Clinical, Journal, HEOR: Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy. (Pubmed Central) - Apr 11, 2019
Trial completion date: May 2019 --> Aug 2019 | Trial primary completion date: Apr 2019 --> Aug 2019 Despite some similar characteristics of newer-generation antiepileptic drugs' effectiveness, levetiracetam stands out with better dynamic improvement of seizure severity and frequency and satisfactory tolerability; typical for pregabalin is a very good dynamic improvement of seizure severity and frequency mainly in patients with focal seizures, but a lower tolerability, and the main advantage of oxcarbazepine is a good tolerability, efficacy, however, is less satisfactory.
- | Preclinical, Journal: Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs. (Pubmed Central) - Apr 7, 2019
The different sensitivities of REDs to these ASDs may reflect persistent molecular, cellular, and/or network-level changes resulting from disease. These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy.
- | Potiga (ezogabine / retigabine) / GSK, Bausch Health
Clinical, Journal: A case report: retigabine induced oral mucosal dyspigmentation of the hard palate. (Pubmed Central) - Mar 29, 2019
Enhanced knowledge of the causative role of retigabine in dyspigementation of the oral mucosa will allow the practitioner to make an appropriate diagnosis. As far the authors are aware this is reaction is unreported in the dental literature and should be disseminated to the wider oral health professional's community.
- | Retrospective data, Journal: Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. (Pubmed Central) - Mar 29, 2019
In this meta-analysis of >9000 patients, those treated with AEDs were more likely than placebo to achieve seizure response or freedom. Patients receiving pregabalin, tiagabine, and vigabatrin had the highest odds of ≥50% reduction in seizures, and patients receiving ezogabine, levetiracetam, and vigabatrin had the highest odds of seizure freedom.
- | Potiga (retigabine) / Bausch Health, GSK
Trial termination: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 (clinicaltrials.gov) - Aug 1, 2018
P3, N=376, Terminated, Sponsor: GlaxoSmithKline
Patients receiving pregabalin, tiagabine, and vigabatrin had the highest odds of ≥50% reduction in seizures, and patients receiving ezogabine, levetiracetam, and vigabatrin had the highest odds of seizure freedom. Active, not recruiting --> Terminated; No longer any benefit in collecting data since retigabine has been withdrawn from market.
- | Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial completion, Enrollment change, Trial completion date: Clinical Trial of Ezogabine (Retigabine) in ALS Subjects (clinicaltrials.gov) - Jul 30, 2018
P2, N=65, Completed, Sponsor: Brian Wainger
Active, not recruiting --> Terminated; No longer any benefit in collecting data since retigabine has been withdrawn from market. Active, not recruiting --> Completed | N=192 --> 65 | Trial completion date: Sep 2018 --> Feb 2018
- || Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial primary completion date: Clinical Trial of Ezogabine (Retigabine) in ALS Subjects (clinicaltrials.gov) - Feb 22, 2018
P2, N=192, Recruiting, Sponsor: Brian Wainger
Active, not recruiting --> Completed | N=192 --> 65 | Trial completion date: Sep 2018 --> Feb 2018 Trial primary completion date: Nov 2017 --> Feb 2018
- || Potiga (retigabine) / Bausch Health, GSK
Trial completion: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Oct 12, 2017
P3, N=30, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Nov 2017 --> Feb 2018 Active, not recruiting --> Completed
- ||||||| Potiga (retigabine) / Bausch Health, GSK
Trial completion: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (clinicaltrials.gov) - Oct 3, 2017
P3, N=98, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Enrollment open: Study to Treat Major Depressive Disorder With a New Medication (clinicaltrials.gov) - Oct 3, 2017
P2, N=48, Recruiting, Sponsor: James Murrough
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Potiga (retigabine) / Bausch Health, GSK
Trial termination: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - Sep 26, 2017
P4, N=10, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Completed --> Terminated
- |||| Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 (clinicaltrials.gov) - Aug 17, 2017
P3, N=376, Active, not recruiting, Sponsor: GlaxoSmithKline
Completed --> Terminated Trial primary completion date: Dec 2016 --> Apr 2017
- |||| Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (clinicaltrials.gov) - Aug 7, 2017
P3, N=98, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Aug 2017 --> Dec 2016
- | Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Jul 17, 2017
P3, N=30, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2017 --> Dec 2016 Trial primary completion date: Jul 2017 --> Dec 2016
- | Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial initiation date: Study to Treat Major Depressive Disorder With a New Medication (clinicaltrials.gov) - Jul 2, 2017
P2, N=48, Not yet recruiting, Sponsor: James Murrough
Trial primary completion date: Jul 2017 --> Dec 2016 Initiation date: Jun 2017 --> Sep 2017
- Potiga (retigabine) / Bausch Health, GSK
Trial completion, Enrollment change, Trial primary completion date: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - Apr 11, 2017
P4, N=10, Completed, Sponsor: GlaxoSmithKline
Initiation date: Jun 2017 --> Sep 2017 Recruiting --> Completed | N=100 --> 10 | Trial primary completion date: Nov 2025 --> Nov 2016
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
New P2 trial: Study to Treat Major Depressive Disorder With a New Medication (clinicaltrials.gov) - Feb 6, 2017
P2, N=48, Not yet recruiting, Sponsor: James Murrough
- |||| Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (clinicaltrials.gov) - Jan 13, 2017
P3, N=100, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=100 --> 10 | Trial primary completion date: Nov 2025 --> Nov 2016 Trial primary completion date: Dec 2020 --> Aug 2017
- || Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial primary completion date: Clinical Trial of Ezogabine (Retigabine) in ALS Subjects (clinicaltrials.gov) - Dec 23, 2016
P2, N=192, Recruiting, Sponsor: Brian Wainger
Trial primary completion date: Dec 2020 --> Aug 2017 Trial primary completion date: May 2017 --> Nov 2017
- | Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Dec 21, 2016
P3, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2017 --> Nov 2017 Trial primary completion date: Dec 2016 --> Jul 2017
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial completion: Study to Treat Major Depressive Disorder (MDD) With a New Medication (clinicaltrials.gov) - Dec 21, 2016
P2, N=18, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2016 --> Jul 2017 Recruiting --> Completed
- | Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Oct 11, 2016
P3, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2016
- Potiga (retigabine) / Bausch Health, GSK
Trial termination, Trial primary completion date: Risk of Urinary Retention With Retigabine (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=1, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2016 --> Dec 2016 Active, not recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Sep 2016; This study was halted as the preliminary analysis revealed that the numbers were too low to warrant continuing the project
- || Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - Sep 29, 2016
P4, N=100, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Sep 2016; This study was halted as the preliminary analysis revealed that the numbers were too low to warrant continuing the project Trial primary completion date: Feb 2019 --> Nov 2025
- |||| Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 (clinicaltrials.gov) - Apr 27, 2016
P3, N=376, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2019 --> Nov 2025 Trial primary completion date: Dec 2015 --> Dec 2016
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial primary completion date: Study to Treat Major Depressive Disorder (MDD) With a New Medication (clinicaltrials.gov) - Apr 14, 2016
P2, N=20, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2016 --> Jan 2017
- ||||||| Potiga (retigabine) / Bausch Health, GSK
Trial completion: Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial (clinicaltrials.gov) - Apr 11, 2016
P3, N=181, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2016 --> Jan 2017 Active, not recruiting --> Completed
- |||| Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (clinicaltrials.gov) - Jan 20, 2016
P3, N=100, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Dec 2020
- || Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - Nov 10, 2015
P4, N=100, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Nov 2015 --> Dec 2020 Trial primary completion date: Dec 2015 --> Feb 2019
- |||| Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Enrollment open: Clinical Trial of Ezogabine (Retigabine) in ALS Subjects (clinicaltrials.gov) - Oct 22, 2015
P2, N=192, Recruiting, Sponsor: Brian Wainger
Trial primary completion date: Dec 2015 --> Feb 2019 Not yet recruiting --> Recruiting
- Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Risk of Urinary Retention With Retigabine (clinicaltrials.gov) - Aug 24, 2015
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Oct 2015
- ||||| Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
New P2 trial: Clinical Trial of Ezogabine (Retigabine) in ALS Subjects (clinicaltrials.gov) - May 21, 2015
P2, N=192, Not yet recruiting, Sponsor: Brian Wainger
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Enrollment open, Trial primary completion date: Study to Treat Major Depressive Disorder (MDD) With a New Medication (clinicaltrials.gov) - May 5, 2015
P2, N=20, Recruiting, Sponsor: Mount Sinai School of Medicine
Trial primary completion date: Jun 2015 --> Oct 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Feb 2016
- Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Risk of Urinary Retention With Retigabine (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Feb 2016 Trial primary completion date: Sep 2014 --> Jun 2015
- Potiga (retigabine) / Bausch Health, GSK
Trial completion, Trial primary completion date: Trobalt (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2014 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2013
- || Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Trial completion: CERETI: Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (clinicaltrials.gov) - Dec 6, 2014
P3, N=15, Completed, Sponsor: University Hospital of Mont-Godinne
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2013 Recruiting --> Completed
- Potiga (retigabine) / Bausch Health, GSK
Trial completion: REMS Retigabine Study (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- Potiga (retigabine) / Bausch Health, GSK
Trial initiation date: Risk of Urinary Retention With Retigabine (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Initiation date: Nov 2010 --> May 2012
- || Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - Jun 17, 2014
P4, N=100, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: Nov 2010 --> May 2012 Trial primary completion date: Mar 2015 --> Dec 2015
- Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Study in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - May 28, 2014
P2, N=5, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Oct 2013 --> Apr 2013
- Potiga (retigabine) / Bausch Health, GSK
Trial termination: Study in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - May 28, 2014
P2, N=5, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2013 --> Apr 2013 Suspended --> Terminated; Terminated after placing the study on hold at the request of the FDA
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
New P2 trial: Study to Treat Major Depressive Disorder (MDD) With a New Medication (clinicaltrials.gov) - May 21, 2014
P2, N=20, Not yet recruiting, Sponsor: Mount Sinai School of Medicine
- ||||| Potiga (retigabine) / Bausch Health, GSK
Enrollment change: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (clinicaltrials.gov) - Apr 16, 2014
P3, N=100, Active, not recruiting, Sponsor: GlaxoSmithKline
Suspended --> Terminated; Terminated after placing the study on hold at the request of the FDA N=140 --> 100
- Potiga (retigabine) / Bausch Health, GSK
Trial termination: Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS (clinicaltrials.gov) - Mar 12, 2014
P3, N=4, Terminated, Sponsor: GlaxoSmithKline
N=140 --> 100 Suspended --> Terminated; FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.
- Potiga (retigabine) / Bausch Health, GSK
Enrollment change: Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS (clinicaltrials.gov) - Mar 12, 2014
P3, N=4, Terminated, Sponsor: GlaxoSmithKline
Suspended --> Terminated; FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results. N=500 --> 4
- | Potiga (retigabine) / Bausch Health, GSK
Enrollment closed: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Mar 12, 2014
P3, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
N=500 --> 4 Recruiting --> Active, not recruiting
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
Enrollment open: CERETI: Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (clinicaltrials.gov) - Dec 29, 2013
P3, N=15, Recruiting, Sponsor: University Hospital of Mont-Godinne
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Potiga (retigabine) / Bausch Health, GSK
Trial initiation date: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Oct 16, 2013
P3, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Initiation date: Jan 2013 --> Apr 2013
- | Potiga (retigabine) / Bausch Health, GSK
Enrollment change: Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (clinicaltrials.gov) - Oct 9, 2013
P3, N=76, Terminated, Sponsor: GlaxoSmithKline
Initiation date: Jan 2013 --> Apr 2013 N=37 --> 76